Brad Hirakawa

842 total citations
18 papers, 566 citations indexed

About

Brad Hirakawa is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Brad Hirakawa has authored 18 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 4 papers in Cardiology and Cardiovascular Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brad Hirakawa's work include Cell death mechanisms and regulation (3 papers), Advanced Breast Cancer Therapies (2 papers) and Retinal Diseases and Treatments (2 papers). Brad Hirakawa is often cited by papers focused on Cell death mechanisms and regulation (3 papers), Advanced Breast Cancer Therapies (2 papers) and Retinal Diseases and Treatments (2 papers). Brad Hirakawa collaborates with scholars based in United States, France and United Kingdom. Brad Hirakawa's co-authors include Bart Jessen, Yvonne Will, Lisa D. Marroquin, James T. Hynes, Shem Patyna, James A. Dykens, Joseph Jamieson, Sashi Nadanaciva, Niel C. Hoglen and Craig D. Fisher and has published in prestigious journals such as Hepatology, Journal of Pharmacology and Experimental Therapeutics and Nature Chemical Biology.

In The Last Decade

Brad Hirakawa

17 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brad Hirakawa United States 10 318 133 96 60 58 18 566
Alex Bell United Kingdom 10 354 1.1× 189 1.4× 119 1.2× 71 1.2× 41 0.7× 12 637
Françoise Gellibert France 8 462 1.5× 157 1.2× 37 0.4× 77 1.3× 62 1.1× 8 730
Devron R. Shah United Kingdom 7 190 0.6× 241 1.8× 88 0.9× 187 3.1× 36 0.6× 8 599
Valérie Martin France 13 219 0.7× 53 0.4× 116 1.2× 75 1.3× 59 1.0× 17 665
Ruth Roberts United Kingdom 4 219 0.7× 150 1.1× 115 1.2× 56 0.9× 24 0.4× 8 498
Yi Ling Teo Singapore 9 228 0.7× 262 2.0× 33 0.3× 130 2.2× 33 0.6× 11 625
Mei Ding China 12 217 0.7× 74 0.6× 78 0.8× 55 0.9× 60 1.0× 41 637
Piia Vuorela Finland 15 374 1.2× 119 0.9× 53 0.6× 98 1.6× 33 0.6× 40 1.2k
Carmelo Blanquicett United States 12 379 1.2× 219 1.6× 28 0.3× 81 1.4× 52 0.9× 17 712
Roberta Sarmiento Italy 11 190 0.6× 235 1.8× 30 0.3× 71 1.2× 26 0.4× 19 591

Countries citing papers authored by Brad Hirakawa

Since Specialization
Citations

This map shows the geographic impact of Brad Hirakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Hirakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Hirakawa more than expected).

Fields of papers citing papers by Brad Hirakawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Hirakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Hirakawa. The network helps show where Brad Hirakawa may publish in the future.

Co-authorship network of co-authors of Brad Hirakawa

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Hirakawa. A scholar is included among the top collaborators of Brad Hirakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Hirakawa. Brad Hirakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Yang, Tangpo, Adolfo Cuesta, Xiaobo Wan, et al.. (2022). Reversible lysine-targeted probes reveal residence time-based kinase selectivity. Nature Chemical Biology. 18(9). 934–941. 63 indexed citations
2.
Lu, Shuyan, et al.. (2020). Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells. Toxicological Sciences. 177(1). 226–234. 5 indexed citations
3.
Thibault, Stéphane, Wenyue Hu, Brad Hirakawa, et al.. (2018). Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology. Molecular Cancer Therapeutics. 18(2). 257–266. 23 indexed citations
4.
Liu, Ling, Shirley A. Aguirre, Winston Evering, et al.. (2014). miR-208a as a Biomarker of Isoproterenol-induced Cardiac Injury in Sod2+/− and C57BL/6J Wild-type Mice. Toxicologic Pathology. 42(7). 1117–1129. 23 indexed citations
5.
Peyster, Ann de, et al.. (2014). Responses of the steroidogenic pathway from exposure to methyl-tert-butyl ether and tert-butanol. Toxicology. 319. 23–37. 9 indexed citations
6.
Rittenhouse, Kay D., Theodore R. Johnson, Paolo Vicini, et al.. (2014). RTP801 Gene Expression Is Differentially Upregulated in Retinopathy and Is Silenced by PF-04523655, a 19-Mer siRNA Directed Against RTP801. Investigative Ophthalmology & Visual Science. 55(3). 1232–1232. 25 indexed citations
7.
Yanochko, Gina M., Allison Vitsky, Jonathan R. Heyen, et al.. (2013). Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction. Toxicological Sciences. 135(2). 451–464. 58 indexed citations
8.
Huang, Jing-Feng, Yi Zhang, & Brad Hirakawa. (2013). Evaluation of JAK inhibition with topical tofacitinib in an experimental autoimmune uveitis model (EAU). Investigative Ophthalmology & Visual Science. 54(15). 2536–2536. 6 indexed citations
9.
Hu, Wenyue, Brad Hirakawa, Bart Jessen, Michelle Lee, & Shirley A. Aguirre. (2012). A tyrosine kinase inhibitor‐induced myocardial degeneration in rats through off‐target phosphodiesterase inhibition. Journal of Applied Toxicology. 32(12). 1008–1020. 6 indexed citations
10.
Rittenhouse, Kay D., Dalia Kalabat, Amy H. Yang, et al.. (2011). Characterization of Regional RTP801 Gene Expression Within the Retina and the Concentration-Effect Relationship of PF-655, an RTP801-silencing siRNA, Following Intravitreous Administration to Diabetic Rats. Investigative Ophthalmology & Visual Science. 52(14). 5641–5641. 1 indexed citations
11.
Taub, Mitchell E., Rucha Sane, Harma Ellens, et al.. (2011). Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells. Drug Metabolism and Disposition. 39(11). 2093–2102. 57 indexed citations
12.
Rittenhouse, Kay D., et al.. (2010). Dose-Related Gene Silencing of RTP801 With the siRNA PF04523655 in Long Evans Rat Models of STZ Induced Diabetes and Laser Induced CNV. Investigative Ophthalmology & Visual Science. 51(13). 6447–6447. 2 indexed citations
13.
Hirakawa, Brad, William R. Scott, G. Jayarama Bhat, et al.. (2010). Antisense Inhibition of S6 Kinase 1 Produces Improved Glucose Tolerance and Is Well Tolerated for 4 Weeks of Treatment in Rats. Pharmacology. 87(1-2). 11–23. 6 indexed citations
14.
Will, Yvonne, James A. Dykens, Sashi Nadanaciva, et al.. (2008). Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells. Toxicological Sciences. 106(1). 153–161. 171 indexed citations
15.
Hirakawa, Brad, et al.. (2008). Toxicogenomic Analysis of Cardiotoxicity in Rats. 1. 4 indexed citations
16.
Hoglen, Niel C., et al.. (2004). Characterization of IDN-6556 (3-{2-(2-tert-Butyl-phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 309(2). 634–640. 75 indexed citations
17.
Hoglen, Niel C., et al.. (2003). 871 IDN-6556, the first anti-apoptotic caspase inhibitor: preclinical efficacy and safety. Hepatology. 38. 579–579.
18.
Hoglen, Niel C., Brad Hirakawa, Craig D. Fisher, et al.. (2001). Characterization of the Caspase Inhibitor IDN-1965 in a Model of Apoptosis-Associated Liver Injury. Journal of Pharmacology and Experimental Therapeutics. 297(2). 811–818. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Bell Breakdown of academic impact, for papers by Françoise Gellibert Breakdown of academic impact, for papers by Devron R. Shah Breakdown of academic impact, for papers by Valérie Martin Breakdown of academic impact, for papers by Ruth Roberts Breakdown of academic impact, for papers by Yi Ling Teo Breakdown of academic impact, for papers by Mei Ding Breakdown of academic impact, for papers by Piia Vuorela Breakdown of academic impact, for papers by Carmelo Blanquicett Breakdown of academic impact, for papers by Roberta Sarmiento
Rankless by CCL
2026